drugset
drugset / Trial / NCT00954876

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

NCT00954876 ↗

Phase 2 Withdrawn Translational Genomics Research Institute Eli Lilly and Company · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with KRAS wild type colorectal cancer. Patients who are not able or willing to take Oxaliplatin/Irinotecan combination therapy are eligible for this study.

Timeline

Start
2009-08
Primary completion
2010-01
Completion
2010-01

Outcome

Outcome not reported

Stopped (Enrollment): “Study halted prematurely, prior to enrollment of first participant”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1500 mg/m2 Oral
Subject Cetuximab Monoclonal antibody 500 mg/m2 Intravenous

Indications

colorectal cancer